Treating Mouse Models of Huntington Disease

Por Tallaksen-Greene, Sara J, Albin, Roger L
Publicado em 2011

Lack of Efficacy of NMDA Receptor-NR2B Selective Antagonists in the R6/2 Model of Huntington Disease

Por Tallaksen-Greene, Sara J., Janiszewska, Anita, Benton, Kasha, Ruprecht, Lech, Albin, Roger L.
Publicado em 2010

The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease

Por Zeng, Li, Tallaksen-Greene, Sara J., Wang, Bo, Albin, Roger L., Paulson, Henry L.
Publicado em 2013

Early autophagic response in a novel knock-in model of Huntington disease

Por Heng, Mary Y., Duong, Duy K., Albin, Roger L., Tallaksen-Greene, Sara J., Hunter, Jesse M., Lesort, Mathieu J., Osmand, Alex, Paulson, Henry L., Detloff, Peter J.
Publicado em 2010

Differential Effects of Delayed Aging on Phenotype and Striatal Pathology in a Murine Model of Huntington Disease

Por Tallaksen-Greene, Sara J., Sadagurski, Marianna, Zeng, Li, Mauch, Roseanne, Perkins, Matthew, Banduseela, Varuna C., Lieberman, Andrew P., Miller, Richard A., Paulson, Henry L., Albin, Roger L.
Publicado no J Neurosci (2014)

Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3

Por Zeng, Li, Wang, Bo, Merillat, Sean A, Minakawa, Eiko, Perkins, Matthew D, Ramani, Biswarathan, Tallaksen-Greene, Sara J., do Carmo Costa, Maria, Albin, Roger L., Paulson, Henry L.
Publicado no Neurobiol Dis (2015)